Scalper1 News
Anika Therapeutics (ANIK) stock vaulted 49% to an all-time high in morning trading on the stock market today, a day after the biotech won FDA approval for its arthritis treatment. After the close Tuesday, Anika said the FDA had approved Monovisc for osteoarthritis of the knee. DePuy Synthes Mitek Sports Medicine, a division of Johnson & Johnson (JNJ), will market Monovisc and pay Anika a $5 million milestone payment, followed by royalties and Scalper1 News
Scalper1 News